Shipping times: Lensabl pledges "about two weeks" turnaround time from when you ship your frames to when you'll receive them back. Until I see the ATHX/BARDA collaboration agreement, I'm not going to pass any judgements on whether the path forward is bold enough, and whether it matches the urgency needed by patients on a ventilator who are fighting for their lives at this very moment, and the new patients who will certainly be fighting for their lives in the weeks ahead. I'm going to re-assess this risk after I see the ATHX/BARDA collaboration agreement, as that agreement should let us know how quickly the MultiStem treatment will move forward. In my view, that designation serves to mitigate this risk. In my opinion, because the MultiStem therapy has a stellar safety profile, has been designated as "Highly Relevant" by BARDA, free mobile adult chat and is the only treatment for ARDS with Fast-Track designation by the FDA, I believe the MultiStem therapy will be adequately funded by BARDA to quickly advance the program to treat Covid-19 patients in need.



2) BARDA just recently gave MultiStem the "Highly Relevant" designation in the 1st quarter of this year. The faster Athersys, BARDA and the FDA work together to get MultiStem approved for ARDS, the more this risk will be mitigated. Data Backup: If most of your important information and free mobile Adult Chat work related stuff are stored in your computer, make sure that you back all of those data up and store them in an external hard drive or store it in a drop box. She also has a graduate education and work experience that has helped. We specialise in building probability models of slot machine games and have experience in the American, Russian, Freemobileadultchat.com German, Swedish and UK markets. They burn approximately $12 million per quarter, so by 3/31/2020 they'll have approximately $23 million in cash, plus any cash raised via their equity line with Aspire. Athersys is a small biotechnology company with 75 employees and a relatively small valuation of $300 million.



Risk of Low Cash Position - Per their SEC filings, Athersys cash position at 12/31/2019 was approximately $35 million. 42 of the corporate presentation (see appendix) is "Complete evaluation / implementation of key partnering initiatives", which implies they expect a deal done before the end of 2020, so that it can be "implemented" before year end 2020. In my view, the pending BARDA agreement will create more partner interest and perhaps competition to be Athersys' partner in Europe. We're in wait-and-see mode to see what the BARDA collaboration agreement may or may not include, on this interesting and forward looking concept. June/July/August - European Partnership (IMO this can come at any time, but management may feel they'll be in a stronger position to sign a deal after the Japan ARDS data is made public. Risk that soon to be released pivotal trial ARDS data from Helios (Athersys' partner in Japan) is not favorable - Data from Helios' pivotal trial treating ARDS patients with MultiStem will likely be released sometime this summer.




Since Helios' ARDS trial is open-label (meaning data is available for Helios to review) it most likely included a review of that data, as Helios and Athersys are partners. In my view, with an open-label trial, confidence would only be expressed if the data was promising. 3) At a recent company presentation, the CEO of Helios expressed confidence that the MultiStem therapy would be approved. The CEO stated "We remain highly focused on achieving our core goals and are making excellent progress. I agree that human beings are better than algorithms (at least for now), but there’s lots of evidence that human beings screw up these curation issues, too, isn’t there? The campaign isn’t political, but fashion-based - the reason Brett, 30, is in LA is that he’s one of the most popular new form of model in the world: the plus-size man. 2020 is NOT one of those years.